ADILADIAL PHARMACEUTICALS, INC.同业对比
ADIAL PHARMACEUTICALS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADIL本股 | $13M#8 | — | — | — | — | 39.5%#7 | — | — | — | — | -46.7%#4 | — |
| REVB | $16M#1 | 0.1x#3 | 1.6x#7 | — | — | 40.7%#5 | — | -88.5%#3 | — | — | — | — |
| MRKR | $16M#2 | — | 1.3x#5 | 4.4x#3 | -46.2%#7 | -13.3%#10 | -363.5%#2 | -100.0%#4 | -1413.6%#4 | — | — | — |
| CTXR | $15M#3 | — | 0.2x#1 | 169.7x#9 | 0.0%#5 | -0.8%#8 | -42806.2%#9 | -59.7%#2 | — | — | -64.3%#7 | — |
| ANEB | $15M#4 | — | 1.9x#8 | — | — | -3.5%#9 | — | -106.9%#5 | — | — | — | — |
| MTNB | $15M#5 | — | 8.1x#14 | 13.3x#4 | -65.6%#8 | 57.3%#2 | -635.0%#4 | -574.7%#14 | — | — | -95.3%#9 | — |
| AEON | $15M#6 | — | — | — | — | -193.4%#15 | — | — | — | — | -65.5%#8 | — |
| ALLR | $14M#7 | 0.0x#1 | 3.9x#12 | 42.6x#8 | — | 54.2%#3 | -3939.1%#7 | -317.6%#12 | — | — | -38.4%#3 | — |
| RKTO | $13M#9 | — | 1.6x#6 | — | — | -52.3%#12 | — | -152.0%#7 | — | — | -63.7%#6 | — |
| BFRI | $13M#10 | — | 2.1x#9 | 0.3x#1 | 11.7%#3 | 40.7%#6 | -27.2%#1 | -176.9%#8 | -712.4%#3 | — | -20.4%#2 | — |
| KAPA | $13M#11 | — | 3.0x#11 | — | — | -109.3%#14 | — | -130.0%#6 | — | — | — | — |
| BOLT | $13M#12 | — | 1.0x#3 | 1.6x#2 | 0.1%#4 | 47.1%#4 | -469.3%#3 | -264.1%#11 | — | — | 11.1%#1 | — |
| KTTA | $12M#13 | — | 0.2x#2 | 25.4x#6 | 3130.4%#1 | -46.9%#11 | -4286.7%#8 | -41.0%#1 | — | — | -53.8%#5 | — |
| HIND | $12M#14 | 0.0x#2 | 4.9x#13 | 38.6x#7 | 24.4%#2 | -609.0%#16 | -3269.4%#6 | -405.7%#13 | -226.2%#2 | — | — | — |
| PPCB | $12M#15 | — | 1.3x#4 | — | — | 68.0%#1 | — | -200.6%#9 | -176.3%#1 | — | — | — |
| VBIO | $12M#16 | — | 2.7x#10 | 14.9x#5 | -33.7%#6 | -57.0%#13 | -1012.6%#5 | -209.1%#10 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议